Like its portfolio companies, Horizon Technology Finance is opportunistic and forward-looking. Taking the long view does more than bridge the financial gap. It allows Horizon’s portfolio companies to get from where they are to where they want to be.
Horizon offers not only the capital a company needs to grow, but a deep understanding of the technology and life science markets, strong relationships in the venture debt and capital industries, a proven financing model and years of experience helping companies and their investors succeed.
Horizon realizes that the success of its portfolio companies is not solely dependent on financing alone. An understanding of their unique growth patterns, along with Horizon’s deep relationships in the venture world, and proven experience getting deals done combine to bring more than just capital to the table.
Horizon leverages its experience, flexibility, financial rigor and optimism to help advance new technologies and build market leading companies. Horizon's team has provided more than $1 billion in venture debt since 2004.
“We welcome the financial partnership of Horizon, an experienced venture lender with a strong balance sheet and long track record of supporting dynamic growth-oriented companies, such as ours.”
David ParatorePresident and CEO of NanoSteel
“Having the right capital at the right time is critical for a growth stage company. Horizon’s flexible financing solution, team of venture lending experts, and smooth and efficient loan closing have provided Interleukin with the strategic capital necessary for its continued growth.”
Dr. Kenneth KornmanCEO of Interleukin Genetics
“In analyzing various sources of funding, Horizon’s experienced venture lending team provided the most attractive value-added loan.”
Stephen T. WillsCFO and Chief Operating Officer of Palatin
“Our long-standing relationship with Horizon made the choice of a venture lender easy as we ready the launch of DURLAZA™.”
Patrick FourteauCEO of NHP
“This attractive loan facility, led by Horizon’s experienced team of venture lending professionals, provides us with a critical source of capital necessary for NinePoint’s future growth.”
Dr. Christopher von JakoPresident and CEO of NinePoint Medical